Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma
Gastric Cancer, Surgery
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring gastric cancer, radiotherapy, postoperative therapy, chemotherapy
Eligibility Criteria
Inclusion Criteria: Histologically proven gastric adenocarcinoma ≥ D2 resection Stage IB(T1N1,T2bN0), II, IIIA, IIIB, IV(T4,N3 포함, M1 lymph node 제외) 18 ≤ age ≤ 75 ECOG 0-2 No distant metastasis Adequate bone marrow functions (ANC ≥ 1,500/ul, blood platelet ≥ 100,000/ul, haemoglobin ≥ 10g/dl) Adequate renal functions(serum creatinine ≤ 1.5mg/dl) liver functions (serum bilirubin ≤ 1.5mg/dl, AST/ALT ≤ 3 times(normal value) Written informed consent Exclusion Criteria: Previous history of immunotherapy, chemotherapy, radiotherapy for gastric cancer Active infection requiring antibiotics Pregnant, lactating women Psychiatric illness, epileptic disorders Concurrent systemic illness not appropriate for chemotherapy Resection margin (+) Pathologic stage IA History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma M1 lymph node (+) D0, D1 resection
Sites / Locations
- Samsung Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
capecitabine/cisplatin/radiotherapy
capecitabine/cisplatin
postoperative XP/RT
postoperative XP